|
Market Closed -
Other stock markets
|
Pre-market 07:05:01 | |||
| 223.6 USD | -1.24% |
|
221.7 | -0.87% |
| 06-13 | REGENXBIO Inc. Announces Chief Executive Officer Changes | CI |
| 06-12 | Biogen executive plays down looming competition for its Alzheimer's drug | RE |
May 30 (Reuters) - Biogen said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophic lateral sclerosis (ALS) drug Qalsody. (Reporting by Sneha S K in Bengaluru; Editing by Alan Barona)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.57% | 32.56B | |
| +1.43% | 94.45B | |
| -0.66% | 38.9B | |
| +71.61% | 28.34B | |
| -12.73% | 15.98B | |
| -2.15% | 13.82B | |
| -13.59% | 11.34B | |
| +158.88% | 9.81B | |
| -52.04% | 9.67B | |
| +2.02% | 8.91B |
BIOGEN INC. 
